Cargando…
Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
INTRODUCTION: It has been proven that ALK‐rearranged non‐small cell lung cancer (NSCLC) is sensitive to ALK inhibitors while the chemotherapy resistance is unavoidable. In this study, safety and antitumor activity of the novel ALK inhibitor (ALKi) CT‐707 were evaluated in Chinese patients with advan...
Autores principales: | Song, Peng, Zhang, Xiaotong, Yang, Dongliang, Wang, Hanping, Si, Xiaoyan, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180692/ https://www.ncbi.nlm.nih.gov/pubmed/32181989 http://dx.doi.org/10.1111/1759-7714.13376 |
Ejemplares similares
-
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021) -
Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
por: Katayama, Ryohei
Publicado: (2018) -
Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population
por: Ying, Jianming, et al.
Publicado: (2015) -
Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement
por: Shukla, Saumya, et al.
Publicado: (2019) -
Pulmonary Spindle Cell Carcinoma Presenting Anaplastic Lymphoma Kinase Rearrangement
por: Sonehara, Kei, et al.
Publicado: (2023)